Maighan Seagrove, DO
Internal Medicine · Chattanooga, TNNPI 1598170797
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,117 of the $77,889 with a category attached, or 73.3%. Novo Nordisk accounts for 84.6% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $45,141 and has fallen 70.3% since, to $13,401 in 2025. Among internal medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 278 payments — averaging $280.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$66K
- Mannkind Corporation$9K
- Amgen$430
- Insulet Corporation$316
- Tandem Diabetes Care, Inc.$230
- Sequel Med Tech, LLC$226
- plus $2K from 24 others
What the payments were for
- Consulting fees$1,7002%
- Speaking & faculty fees$57,11773%
- Travel & lodging$13,27117%
- Food & beverage$5,7587%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 104 | $65,929 |
| Mannkind Corporation | 36 | $8,769 |
| Amgen(2 entities) | 14 | $430 |
| Insulet Corporation | 23 | $316 |
| Tandem Diabetes Care, Inc. | 7 | $230 |
| Sequel Med Tech, LLC | 9 | $226 |
| Cequr Corporation | 2 | $215 |
| Lilly USA, LLC | 15 | $214 |
| Xeris Pharmaceuticals, Inc. | 4 | $179 |
| Corcept Therapeutics | 5 | $171 |
| Medtronic | 8 | $147 |
| Novartis | 8 | $141 |
| Ascendis Pharma Endocrinology Inc | 8 | $137 |
| RGH Enterprises LLC | 1 | $109 |
| Dexcom, Inc. | 4 | $101 |
| Bayer | 4 | $84 |
| AbbVie | 5 | $75 |
| AstraZeneca | 4 | $63 |
| Madrigal Pharmaceuticals | 2 | $57 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Abbott | 2 | $42 |
| Amneal Pharmaceuticals LLC | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Astellas Pharma US Inc | 1 | $24 |
| Antares Pharma, Inc. | 1 | $24 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| Acella Pharmaceuticals, LLC | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Nevro Corp. | 1 | $16 |
| Intra-sana Laboratories | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$28,974
- RYBELSUS$15,468
- Saxenda$11,991
- Ozempic$8,573
- AFREZZA$8,322
- EVENITY$238
- CeQur Simplicity$187
- RECORLEV$135
- Korlym$105
- t:slim X2 Insulin Pump with Control-IQ$100
How this compares
$77,889 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 344 | $595,839 |
| JardianceEmpagliflozin | 267 | $334,039 |
| Tresiba Flextouch U-200Insulin Degludec | 98 | $222,580 |
| Tresiba Flextouch U-100Insulin Degludec | 120 | $149,251 |
| MounjaroTirzepatide | 92 | $123,955 |
| FarxigaDapagliflozin Propanediol | 44 | $62,100 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $59,659 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $48,822 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $42,811 |
| Novolog FlexpenInsulin Aspart | 67 | $36,510 |
| RybelsusSemaglutide | 20 | $36,368 |
| Humalog Kwikpen U-100Insulin Lispro | 65 | $36,255 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 45 | $35,323 |
| TrulicityDulaglutide | 15 | $30,669 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $24,446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $65,929 | $639,208380 claims |
| Boehringer IngelheimJardiance | $31 | $334,039267 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $214 | $179,003130 claims |
| AstraZenecaFarxiga | $63 | $62,10044 claims |
| AbbVieSynthroid | $75 | $7,31581 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $32 | $4,610451 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Chattanooga
- Carlton VollbergChattanooga$30K
- Jeremy HogstromChattanooga$30K
- Jermaine HogstromChattanooga$29K
- Eugene RyanChattanooga$26K
- John AndersonNashville$1.5M
- Tracie WalkerJackson$488K
- Nathan TrenthamEtowah$404K
- Dennis DeruelleKnoxville$263K
- Devin ShermanFranklin$191K
- Lewis HagoodKnoxville$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.